Orion Corporation's 2025 AGM Nomination Committee Recommendations

Insights from Orion Corporation's Nomination Committee

Orion Corporation is gearing up for its upcoming Annual General Meeting (AGM) in 2025. As part of the preparations, the Nomination Committee has made some significant recommendations concerning the future of its Board of Directors. The recommendations made are not only pivotal for the company’s governance but also demonstrate its continued commitment to effective leadership.

Proposed Composition for the Board of Directors

The Nomination Committee has proposed that the Board of Directors be composed of eight members, ensuring a robust and diverse mix of expertise. Reappointment of the current Board members is part of this recommendation, which includes notable figures such as Kari Jussi Aho, Maziar Mike Doustdar, Ari Lehtoranta, Veli-Matti Mattila, Hilpi Rautelin, Eija Ronkainen, Henrik Stenqvist, and Karen Lykke Sørensen.

Chairman Election

Furthermore, Veli-Matti Mattila is recommended for re-election as the Chairman of the Board, a role he has held during his tenure, showcasing strong leadership and clear strategic vision.

Remuneration for the Board Members

As part of the recommendations, the Nomination Committee has outlined the remuneration structure for the Board members, which includes both annual fees and meeting attendance fees. The proposed fees reflect a commitment to recognizing the efforts and responsibilities of board members, helping to ensure that the Board remains motivated and engaged.

Annual Fees Breakdown

The fee structure is as follows: the Chairman is set to receive EUR 112,000 annually, with the Vice Chairman earning EUR 68,500, while each other Board member is proposed to receive EUR 56,000. Interestingly, those who chair key committees like the Audit Committee or the R&D Committee will be compensated at a rate of EUR 68,500.

Attendance Fees

To further acknowledge the dedication of its members, an attendance fee structure is also in place. The Chairman's meeting attendance fee is suggested to be EUR 1,200, a rate that promotes active participation. The Vice Chairman's fee would amount to EUR 900, while other committee members would receive EUR 600 per meeting.

Share-Based Compensation

In a notable move towards aligning interests with shareholders, 60% of the proposed annual fees will be paid in cash, while the remaining 40% will be converted into Orion Corporation B shares. This strategic approach also entails acquiring these shares during a specified trading period, reinforcing the importance of ownership among Board members.

Retention Policy for Shares

To enhance long-term commitment, Board members receiving shares as part of their remuneration will be required to hold them for a minimum of two years. This retention policy ensures that members have a vested interest in the company's sustained success and growth.

Financial Responsibilities and Considerations

Orion Corporation has committed to covering potential statutory social security and pension costs for Board members based outside of Finland, reflecting its comprehensive approach to governance. The transfer tax related to share payments will also be borne by the company, which is indicative of its commitment to transparency and fairness.

Nomination Committee's Role

Notably, the Nomination Committee has functioned effectively throughout this process. Composed of members who do not participate in discussions regarding their remuneration, this structure exemplifies independence and the integrity of the recommendations provided.

About Orion Corporation

Orion Corporation, a Finnish pharmaceutical giant, has a legacy that spans over a century in boosting well-being through its innovative products. The company develops, manufactures, and markets an extensive range of human and veterinary medications as well as pharmaceutical ingredients. Orion’s core research areas primarily focus on oncology and pain management, with proprietary products dedicated to treating critical health conditions.

Current Business Landscape

With net sales reaching EUR 1,190 million in 2023 and a workforce of about 3,600 employees, the company is positioned as a key player in the pharmaceutical industry. Orion’s shares are publicly traded on Nasdaq Helsinki, appealing to a broad spectrum of investors interested in a solid and impactful healthcare company.

Frequently Asked Questions

What recommendations has the Nomination Committee made for 2025?

The Committee recommends a Board of Directors consisting of eight members and proposes the re-election of current members.

Who is proposed to continue as Chairman of the Board?

Veli-Matti Mattila is recommended for re-election as Chairman of the Board.

What is the proposed remuneration for Board members?

The Chairman would earn EUR 112,000 annually, while other members would receive EUR 56,000, along with meeting attendance fees.

How will Board member remuneration be structured?

60% of the fees will be in cash, with 40% converted to Orion Corporation B shares to align interests with shareholders.

Where can I find more information about Orion Corporation?

Further details about Orion Corporation and its operations can be found on their official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.